GENFIT (GNFT.PA)
FR0004163111 - Common Stock
GNFT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. GNFT has a bad profitability rating. Also its financial health evaluation is rather negative. GNFT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GNFT has reported negative net income.
In the past year GNFT has reported a negative cash flow from operations.
In the past 5 years GNFT reported 4 times negative net income.
In the past 5 years GNFT reported 4 times negative operating cash flow.
1.2 Ratios
GNFT has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT has a Gross Margin of 92.00%. This is amongst the best in the industry. GNFT outperforms 91.89% of its industry peers.
In the last couple of years the Gross Margin of GNFT has grown nicely.
The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM | N/A | ||
| GM | 92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y6.39%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GNFT remains at a similar level compared to 1 year ago.
Compared to 5 years ago, GNFT has more shares outstanding
Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
GNFT has an Altman-Z score of -1.19. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT has a worse Altman-Z score (-1.19) than 66.22% of its industry peers.
A Debt/Equity ratio of 0.74 indicates that GNFT is somewhat dependend on debt financing.
GNFT has a worse Debt to Equity ratio (0.74) than 63.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.19 |
ROIC/WACCN/A
WACC6.45%
2.3 Liquidity
GNFT has a Current Ratio of 4.02. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT's Current ratio of 4.02 is fine compared to the rest of the industry. GNFT outperforms 70.27% of its industry peers.
A Quick Ratio of 4.02 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a better Quick ratio (4.02) than 75.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 |
3. Growth
3.1 Past
The earnings per share for GNFT have decreased strongly by -146.00% in the last year.
Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -68.18% in the last year.
Measured over the past years, GNFT shows a very strong growth in Revenue. The Revenue has been growing by 31.11% on average per year.
EPS 1Y-146%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-120.09%
Revenue growth 1Y-68.18%
Revenue growth 3Y-13.44%
Revenue growth 5Y31.11%
Revenue growth Q2Q-82.04%
3.2 Future
GNFT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.97% yearly.
GNFT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.76% yearly.
EPS Next Y89.07%
EPS Next 2Y44.21%
EPS Next 3Y21.97%
EPS Next 5YN/A
Revenue Next Year189.66%
Revenue Next 2Y55.87%
Revenue Next 3Y29.41%
Revenue Next 5Y43.76%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
Also next year GNFT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GNFT's earnings are expected to grow with 21.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.21%
EPS Next 3Y21.97%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENFIT
EPA:GNFT (9/22/2023, 7:00:00 PM)
3.17
-0.1 (-2.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap157.98M
Analysts90
Price Target9.86 (211.04%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)68.11%
Min EPS beat(2)68.11%
Max EPS beat(2)68.11%
EPS beat(4)1
Avg EPS beat(4)33.7%
Min EPS beat(4)-0.71%
Max EPS beat(4)68.11%
Revenue beat(2)1
Avg Revenue beat(2)103815%
Min Revenue beat(2)103815%
Max Revenue beat(2)103815%
Revenue beat(4)1
Avg Revenue beat(4)51878.1%
Min Revenue beat(4)-58.8%
Max Revenue beat(4)103815%
PT rev (1m)0%
PT rev (3m)22.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)33.03%
EPS NY rev (3m)47.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)4.72%
Revenue NY rev (3m)20.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.67 | ||
| P/tB | 3.12 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.46
OCFYN/A
SpS0.53
BVpS1.9
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 92% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y6.39%
F-Score0
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.02 | ||
| Quick Ratio | 4.02 | ||
| Altman-Z | -1.19 |
F-Score0
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-146%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-120.09%
EPS Next Y89.07%
EPS Next 2Y44.21%
EPS Next 3Y21.97%
EPS Next 5YN/A
Revenue growth 1Y-68.18%
Revenue growth 3Y-13.44%
Revenue growth 5Y31.11%
Revenue growth Q2Q-82.04%
Revenue Next Year189.66%
Revenue Next 2Y55.87%
Revenue Next 3Y29.41%
Revenue Next 5Y43.76%
EBIT growth 1Y-190.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.45%
EBIT Next 3Y14.79%
EBIT Next 5YN/A
FCF growth 1Y-173.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-172.7%
OCF growth 3YN/A
OCF growth 5YN/A